MedAdvisor projects its FY24 revenue to be between $120 million and $123 million, a substantial increase from FY23's $98 million.

EBITDA for the fiscal year ending June 30 is expected to reach $6.8 million to $7.6 million, up by approximately $10 million from the prior year.

Net profit after tax is estimated to range from $500,000 to $800,000, contrasting sharply with FY23's $11.3 million loss.

Growth drivers include strong contributions from the THRiV program in the US and heightened transaction fees in Australia.